Addex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026
Summary
Ad Hoc Announcement Pursuant to Art. 53 LR
Description
Ad Hoc Announcement Pursuant to Art. 53 LR
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source